This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Milford, MA-based, Waters Corp. is an analytical instrument manufacturer and offers practical and sustainable products for laboratory-dependent organizations. Moreover, Waters provides analytical workflow solutions based on mass spectrometry (MS), liquid chromatography (LC) and thermal analysis technologies. The company’s products are used by pharmaceutical, life science, biochemical, industrial, academic and government customers, working in research and development, quality assurance and other laboratory applications. The company operates in Asia, Americas and Europe. Waters organizes its business into two operating segments: Waters Division and TA Division. Waters Division (88.8% of total revenues in 2019) - High Performance and Ultra Performance Liquid Chromatography (HPLC and UPLC). TA Division (11.2% of total revenues in 2019)- Thermal Analysis, Rheometry and Calorimetry.
Waters (WAT) Up 5.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of +0.68% and +3.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Waters (WAT) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of +8.89% and +0.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Waters (WAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BD Partners With Waters to Build High-Volume Diagnostics Leader
by Zacks Equity Research
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
Why Waters (WAT) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Waters (WAT) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Waters (WAT) Up 2.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Waters (WAT) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
by Zacks Equity Research
WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.
Waters (WAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Waters (WAT) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Waters (WAT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 1.35% and 1.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Sensus Healthcare (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Analyst Projections for Key Metrics Reveal About Waters (WAT) Q1 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Waters (WAT) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 1.37% and 1.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.